A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Fluorouracil (5-FU) in Patients with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine.

  • For patients with metastatic pancreatic cancer who have already progressed or failed therapy on a gemcitabine-based first line regimen
  • The study is designed to assess whether an investigational drug Glufosfamide provides additional survival benefit as compared to Fluorouracil (5-FU) in patients
  • Investigational drug Glufosfamide is provided by the study

Contact Candace LeBlanc 508-556-5431 or Marcy Kirkpatrick 508-556-5429 for more information.

For more information about this study: